Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy

Published:2023 Issue:4 Volume:12 Page:289-296
ISSN:2235-1795
Container-title:Liver Cancer
language:en
Short-container-title:Liver Cancer

Author:

Kudo Masatoshi

Publisher

S. Karger AG

Subject

Oncology,Hepatology

Link

https://karger.com/lic/article-pdf/doi/10.1159/000532023/3995954/000532023.pdf

Reference61 articles.

1. Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)

2. Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update

3. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type

4. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion

5. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis;Cytokine & Growth Factor Reviews;2024-10

2. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab;Journal of Clinical Oncology;2024-08-28

3. Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma;Liver Cancer;2024-08-12

4. Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma;Liver Cancer;2024

5. A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization);Liver Cancer;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3